Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know
Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.
Moderna (MRNA) stock is plunging Thursday after the COVID-19 vaccine maker announced plans to slash research and development (R&D) expenses and instead focus on receiving approvals for the many drugs in its pipeline.
Moderna's plans include a $1.1 billion reduction in R&D expenses by 2027 to a range of $3.6 billion to $3.8 billion. Rather than spending to explore new products, the company will shift its focus to winning approvals for the 10 products in its pipeline.
"Moderna now has five respiratory vaccines with positive Phase 3 results and expects to submit three for approval this year," said Moderna CEO Stéphane Bancel in a statement. "In addition, we have five non-respiratory products in pivotal studies across cancer, rare diseases and latent vaccines with potential for approval by 2027."
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Bancel adds that "the size of our late-stage pipeline combined with the challenge of launching products means we must now focus on delivering these 10 products to patients, slow down the pace of new R&D investment, and build our commercial business."
The shift in strategy comes as Moderna has seen a sharp decline in sales of its COVID-19 vaccine, including a 37% year-over-year decrease in its most recent quarter.
In the release, Moderna also said it anticipates fiscal 2025 revenue to be in the range of $2.5 billion to $3.5 billion and sales to grow at a 25% compound annual growth rate from 2026 to 2028, "driven by new product launches."
The midpoint of MRNA's revenue outlook for its upcoming fiscal year, $3 billion, came in well below analysts' expectations. Wall Street is expecting revenue of $3.74 billion in fiscal 2025, according to Yahoo Finance.
Is Moderna stock a buy, sell or hold?
Moderna had a good run up the price charts to start 2024, but the healthcare stock is now down 33% for the year to date. Still, Wall Street remains bullish on the drugmaker.
According to S&P Global Market Intelligence, the consensus analyst target price for MRNA stock is $125.71, representing implied upside of more than 90% to current levels. Additionally, the consensus recommendation is Buy. However, analysts may revise their targets lower following the reaction to its updated R&D plans.
And some analysts are already on the sidelines when it comes to the large-cap stock, including financial services firm William Blair, which has a Market Perform rating (equivalent to a Hold) on MRNA.
"Like other biotechnology companies with development pipelines, Moderna's risks center on commercial, regulatory, and clinical development," said William Blair analyst Myles Minter in an August 16 note.
The analyst adds that key risks specific to Moderna include the "potential for greater-than-anticipated drop-off in the COVID market, possible failure to show equivalent efficacy across various flu strains versus currently available and other emerging flu vaccines, poor tolerability and/or efficacy with repeat mRNA therapeutics dosing, and other potential clinical setbacks including failed or delayed trials."
Related Content
-
I have a secret second family. Can my estate cover everyone confidentially?We asked estate planning experts how to keep this skeleton in the closet.
-
Social Security: Are You and Your Financial Adviser in Sync?Deciding when to claim Social Security is tricky if you and your adviser haven't thoroughly covered the topic. Here's how to ensure you're on the right track.
-
How to Find the Best International Moving CompanyIt's best to use an international moving company to protect your belongings and budget when relocating to another country. Here's how to find a reputable firm.
-
Are You and Your Financial Adviser in Sync on Social Security?
Deciding when to claim Social Security is tricky if you and your adviser haven't thoroughly covered the topic. Here's how to ensure you're on the right track.
-
How to Find the Best International Moving Company for Your Big Move Abroad (and Avoid Costly Mistakes)
It's best to use an international moving company to protect your belongings and budget when relocating to another country. Here's how to find a reputable firm.
-
Dow Soars 588 Points as Trump Retreats: Stock Market TodayAnother up and down day ends on high notes for investors, traders, speculators and Greenland.
-
7 Hybrid Adviser Services, ReviewedThese hybrid adviser services aim for a sweet spot that combines digital investing with a human touch.
-
If You'd Put $1,000 Into UPS Stock 20 Years Ago, Here's What You'd Have TodayUnited Parcel Service stock has been a massive long-term laggard.
-
5 Ways Trump Could Impact Your Portfolio This YearInvestors are facing a changing landscape this year, from lower interest rates to a massive tax and spending bill. Here's how to prepare your portfolio.
-
This Overlooked Diversification Tool Can Build Resilience Into Your PortfolioMunicipal bonds can provide a steady income and stability that's separate from federal shifts and global economic headwinds.
-
What Will Happen to Your Business When You Retire? How to Exit Successfully and Thrive in RetirementStepping away from work is extra challenging when you're a business owner, and a successful retirement requires planning that looks beyond the financials.
